Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

How Do Delays in Cancer Screening and Treatment During the Pandemic Affect Mortality Rates?

How Do Delays in Cancer Screening and Treatment During the Pandemic Affect Mortality Rates?

Regular cancer screening for early diagnosis is the most important part of cancer prevention and early diagnosis. However, beginning in 2020, the Covid-19 Pandemic negatively affected regular cancer screening, as it did many other things.

A study conducted in the United States showed a substantial reduction in hospital cancer screening tests and biopsies during the 7-week pandemic period between January-February 2020.

The study, involving 278,778 patients, examined ICD-10 codes for newly diagnosed breast, colorectal (large bowel), lung, pancreatic, stomach, and esophageal cancers entered weekly between January 1, 2018 and April 18, 2020. Average weekly diagnosis numbers were determined for each cancer. These were then compared with the weekly averages during the pandemic's first 7 weeks.

Of the patients recorded in the study, 7.2% were from the Covid-19 pandemic period. For all 6 cancers combined, the weekly number of diagnoses during the pandemic compared with the baseline period decreased by 46.4%.

In terms of follow-up records or diagnosis, the largest decline, 51.8%, was in breast cancer cases. Pancreatic cancer had the smallest decline (24.7%). The situation was similar in countries outside America. During Covid-19 restrictions, weekly frequency of follow-ups for suspected cancer decreased by 40% in the Netherlands and 75% in England.

Data from other private health centers were similar. San Francisco-based healthcare analytics company Komodo Health examined billing records for 320 million patients. According to these records, colonoscopies and biopsies compared with figures from 2019, by mid-April decreased by nearly 90%. New colorectal cancer diagnoses were 32% lower in mid-April compared with 2019. Colorectal operations also decreased by 53% compared with 2019.

Yet in the pandemic's first months, medical organizations worldwide had agreed on postponing routine screenings for a while. It was thought that delaying March-April visits by a month or two would cause no harm. Thus, it was assumed that a 3-4 month delay in colonoscopy, recommended every 10 years, or, for the test recommended every 2 years—mammography—a postponement of 4 months would not be very important.

Now the scientific community has begun asking, “Is simply delaying routine screenings giving way to entirely missed screening?” as a question.

Can a simple screening delay really turn into a missed opportunity?

The United States National Cancer Institute (US-NCI) is concerned that, if current trends continue, cancer deaths, which have been observed to decline annually since 1990, will increase.

According to Dr. Sharpless, one of the physicians commenting on the study, "When breast and colorectal cancer screenings decline by an average of 75% over 6 months, this could increase breast and colorectal cancer deaths by 1% over the next 10 years. This would mean more than approximately 10 thousand deaths within 10 years, or more than 1000 additional deaths per year from breast and colorectal cancer alone".

Detecting cancer early through screening naturally affects the treatments applied (chemotherapy, radiotherapy, surgery), treatment duration, quality of life, and life expectancy. However, the situation differs when cancer is detected at an advanced (metastatic) stage.

Dr. Timothy P. Hanna believes that a 4-week delay in cancer treatment increases cancer mortality. Dr. May says, “If a patient is diagnosed with colon cancer at stage 1, they have a 90% chance of survival. However, if the same patient is not diagnosed until stage 4, the 5-year survival rate falls to 11%. Therefore, the stage at diagnosis really matters. We want patients not to delay cancer screenings, because existing cancer continues to grow and spread when it is not detected early”.

In June 2020, the American Society of Clinical Oncology (ASCO) recommended postponing cancer screening procedures requiring clinical visits, such as mammography and colonoscopies, "for now". Because Covid-19 continues, the webpage containing this recommendation has not been updated since June 22, 2020.

Dr. Bunnell says they do not know when the pandemic will end, and therefore, “Screening tests should not be postponed. Checkups must continue, whether face to face in hospitals or through telehealth applications as a means of maintaining follow-up”.

Conclusion

In conclusion, the pandemic is still ongoing. However, cancer screenings recommended for individuals according to their age and risk profile must not be neglected. Although telehealth appears somewhat helpful, mammography, colonoscopies, laboratory tests, and physical examinations used for early cancer diagnosis must be completed. We therefore recommend that patients attend hospitals to receive healthcare. Hospitals and other health centers should also organize the physical areas where examinations are performed according to Covid-19 procedures to ensure safe use.

*

RELATED TOPICS

Sources

1. Lai A, Pasea L, Banerjee A, et al. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. April 2020.

2. Cavallo J. How delays in screening and early cancer diagnosis amid the COVID-19 pandemic may result in increased cancer mortality: A conversation with NCI director Norman E. ‘Ned’ Sharpless, MD. The ASCO Post. Published September 10, 2020. Accessed December 1, 2020.

3. Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw Open. 2020;3(8):e2017267.

4. Komodo Health. New colorectal cancer diagnoses fall by one-third as colonoscopy screenings and biopsies grind to a halt during height of COVID-19. Research brief. Published May 2020. Accessed December 1, 2020.

5. Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087.

6. American Society of Clinical Oncology (ASCO). Cancer screening, diagnosis, staging & surveillance. Updated June 22, 2020. Accessed December 1, 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

How Do Delays in Cancer Screening and Treatment During the Pandemic Affect Mortality Rates?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy